As a natural flavonol, fisetin has significant inhibitory effects on many cancers.
| INTRODUCTION
Renal cell carcinoma (RCC) is the most common primary renal parenchymal malignancy in adults. RCC originates in the epithelial cells in the proximal convoluted tubule and its incidence is second only to bladder cancer among urogenital cancers, accounting for 2%-3% of human tumours, and 80%-90% of malignant tumours of the kidney. [1] [2] [3] [4] [5] RCC has high malignancy and poor prognosis, which severely threatens human health. [2] [3] [4] [5] The appearance of RCC is due to a series of clinical malignant transformations in kidneys at the pathological and molecular levels. [1] [2] [3] [4] [5] Clear cell carcinoma and papillary carcinoma (Types 1 and 2) account for most types of RCCs. [1] [2] [3] [4] [5] Recent studies have shown that the occurrence of RCC is intimately associated with aberrant activation of many signal transduction pathways and aberrant gene methylation. [1] [2] [3] [4] [5] DNA methylation refers to the epigenetic modification in which a methyl group is added at the cytosine (C) of DNA to form methylcytosine. 6, 7 DNA methylation is intimately associated with cancer occurrence and development. 6, 7 Changes in DNA methylation include hypermethylation and hypomethylation. 6, 7 Generally, hypermethylation of promoter DNA indicates that the gene is silenced, whereas hypomethylation indicates that the gene is activated. 6, 7 As an important epigenetic modification, DNA methylation participates widely in the regulation of gene expression, histone modification and other processes. 6, 7 In many in vivo and in vitro reprogramming processes, removal of DNA methylation is extremely important in the activation of totipotent genes and reconstruction of histone modifications. 6, 7 The ten-eleven translocation (TET) protein family contains three members, namely Tet1, Tet2 and Tet3. [8] [9] [10] These three proteins contain a conserved C-terminal catalytic domain and classical characteristics of 2-oxoglutarate-and Fe (II)-dependent dioxygenases. 8, 9 The dioxygenases in the TET family can gradually oxidize 5-methylcytosine (5mC)
in mammalian genomes to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). 6, 7, 9, 10 Thymine-DNA glycosylase (TDG) in mammals is responsible for recognition and excision of 5fC and 5caC. TDG carries out base excision repair to restore them to normal cytosine. 6, 7 Recent studies showed that TET2 mutations are present in around 6% of patients with RCC. Compared with normal tissues, 5mC accumulation occurs in TET-mutated tumours. 11 By profiling genome 5mC and 5hmC levels in genomes, in tissues using single nucleotide resolution, researchers have proved that some 5mC is present in the genome of renal cancer tissues compared with normal tissues. However, there is significant 5hmC loss in renal cancer tissues.
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At the same time, studies have shown that 5hmC level in renal cancer tissues is an independent prognostic marker for renal cancer. 5hmC levels are intimately associated with overall survival.
Cell division requires joint regulation by cyclin-dependent kinases 10 ng/mL basic fibroblast growth factor, 10 ng/mL epidermal growth factor, 5 μg/mL insulin, 1% bovine serum albumin (BSA) and 5% knockout serum replacement (KnockOut SR) (all in Gibco).
| HE staining
In brief, 1 4 μ thick sections were cut from paraffin blocks and pasted to slides. Xylene was used for clearing and unequal concentrations of ethanol were used for dehydration. Haematoxylin was added and the slides were stained for 5 minutes before differentiation using hydrochloric acid in ethanol. This is followed by bluing using ammonium solution, followed by washing with distilled water for 10 minutes. Following that, eosin was added and the slides were stained for 2 minutes before washing with distilled water for 10 minutes.
Ethanol dehydration was carried out, followed by xylene clearing for 2 minutes, and sealing using neutral resin.
| Immunofluorescence staining
In brief, 4% paraformaldehyde was added to cell or tissue sections for fixing at room temperature for 40 minutes, followed by antigen retrieval, after which blocking solution (PBS containing 0.5% Triton X-100 and 5% goat serum) was added for blocking at 37°C for 40 minutes. Primary antibodies (Table S1 ) were then added and allowed to react at 37°C for 40 minutes. The wash solution (PBS containing 0.5% Triton X-100) was used to wash the sections thrice at room temperature, for 5 minutes each time. Secondary antibodies (Table S1) for 30 minutes before a flow cytometer (Cytomics FC 500; BECK-MAN) was used for detection.
| Methyl thiazolyl tetrazolium assay
In brief, 1 the number of cells in various groups was adjusted and 2 × 10 3 /mL of cells was subcultured onto a 96-well cell culture plate.
On the second day, 20 μL of methyl thiazolyl tetrazolium (MTT;
Sigma-Aldrich Chemical) solution was added to various groups and incubated at 37°C for 3 hours. The culture medium was discarded and 100 μL DMSO was added to dissolve formazan. The cell culture plates were placed in a microplate reader and the absorbance at 570 nm was recorded. The calculation formula for inhibition rate of cell proliferation (%) is: (1-OD value of cells in the experiment group/ OD of cells in the control group) × 100%.
| PI stain and FCM assay
In brief, 1 
| In vivo xenograft experiments
In brief, 1 The mRNA expression levels were corrected using the 18s rRNA SI ET AL.
expression levels. The primers required for the amplification of each gene were described in previous studies.
1,9,12,14,15
| Western blot
In brief, 1 the total proteins from cells from various groups were run on a 12% denaturing SDS-PAGE gel. After electrophoresis was completed, the proteins were transferred into PVDF membranes (Millipore). After blocking and washing, the membranes were incubated with primary antibodies at 37°C for 45 minutes (Table S1) .
After complete washing, the membranes were incubated with secondary antibodies at 37°C for 45 minutes. The membranes were washed four times with TBST, for 14 minutes per wash. Following that, enhanced chemiluminescence (ECL) (ECL kit, Pierce Biotechnology) was used for exposure and development (Sigma-Aldrich Chemical).
| Dot blot
In brief, 9 total DNA was extracted from cells in various groups and the DNA concentration was adjusted to 600 ng/μL. DNA suspension (2 μL) was added to a cationic membrane before UV cross-linking for 40 seconds, followed by drying at 80°C for 30 minutes. Following that, blocking solution (PBS containing 0.05% Tween-20, and 5%
BSA) was used for blocking at room temperature for 3 hours. Primary antibodies (Table S1) were then added and allowed to react at 4°C overnight. The wash solution (PBS containing 0.05% Tween-20)
was used to wash the membranes thrice at room temperature, for 15 minutes each time. HRP-labelled secondary antibodies (Table S1) were then added and allowed to react at 37°C for 40 minutes. The membranes were washed thrice at room temperature, for 15 minutes each time. Following that, ECL (ECL kit; Pierce Biotechnology) was used for exposure and development.
3 | RESULTS
| TET1 is highly expressed in renal cancer tissues
We collected renal cancer tissue samples from 50 patients to generate a tissue microarray ( Figure 1A) . Through HE staining, we selected three tissues from the tissue microarray, which represent clear cell RCC, papillary RCC and chromophobe RCC as study cases ( Figure 1A ). Immunofluorescence staining results showed that TET1
protein is highly expressed, regardless of the type of renal cancer tissue ( Figure 1B) . Through flow cytometry, we obtained the CD44+/CD105+ renal cancer stem cell (HuRCSCs) subpopulation.
This subpopulation accounted for an extremely low proportion of the entire renal cancer tissue (around 0.65 ± 0.11%) ( Figure 1C-E) .
In addition, FCM results showed that renal cancer cells co-expressing TET2 and CD44 accounted for 1.82 ± 0.15% of the entire cell population. Immunofluorescence staining and identification showed that the HuRCSCs obtained from screening have a high expression of the CD44 and CD105 markers ( Figure 1D and E, Figure S1 ). It can be seen that TET1 expression is positively correlated with the degree of malignancy of renal cancer and is highly expressed in HuRCSCs.
| Fisetin inhibits in vivo and in vitro activity of HuRCSCs
According to the results of previous studies, we selected the recommended IC50 concentration (50 μmol/L) to treat HuRCSCs. 19, 20 MTT assay results showed that cell proliferation was inhibited after fisetin was co-cultured with HuRCSCs for 12 hours. As co-culture duration increases, inhibition of cell proliferation significantly increased. Compared with the control group (DMSO), this difference was statistically significant (Figure 2A 
| Fisetin inhibits TET1 expression and genomic 5hmC levels in HuRCSCs
Firstly, dot blot was used to determine genomic 5hmC levels in
HuRCSCs. The experiment results showed that genomic 5hmC levels in CD44+/CD105+ HuRCSCs were significantly higher than those in CD44-/CD105-HuNRCCs ( Figure 4A ). However, the genomic 5hmC levels of the HuRCSCs that were pre-treated with fisetin for 48 hours were significantly lower than those of cells The volume of tumours formed in the fisetin treatment group was significantly smaller than those formed from the control group. **P < 0.01 vs physiological saline group; n = 3; t test. (H) The weight of tumours formed in the fisetin treatment group was significantly smaller than those formed from the control group. **P < 0.01 vs physiological saline group; n = 3; t test F I G U R E 3 Fisetin inhibits in vivo proliferation and angiogenesis in HuRCSCs. Magnification: 200×. **P < 0.01 vs physiological saline group; n = 3; t test. Scale bar = 30 μm F I G U R E 4 Fisetin inhibits TET1 expression and 5hmC modification levels in the genomes of HuRCSCs. (A) Dot blot results showed that HuRCSCs have a significantly higher genomic 5hmC level than HuNRCCs. **P < 0.01 vs HuNRCCs; n = 3; t test. (B) The genome 5hmC levels of the fisetin treatment group were significantly lower than cells from the control group. **P < 0.01 vs DMSO group; n = 3; t test. (C) qPCR results showed that HuRCSCs have significantly higher Tet1 mRNA levels than HuNRCCs. **P < 0.01 vs HuNRCCs; n = 3; t test. (D) qPCR results showed that fisetin significantly decreases endogenous Tet1 mRNA levels in HuRCSCs. **P < 0.01 vs DMSO group; n = 3; t test. (E) Western blotting results showed that HuRCSCs have a significantly higher expression of TET1 protein than HuNRCCs. However, fisetin significantly inhibits the expression of endogenous TET1 in HuRCSCs experiment results showed that among the complexes that crosslink with the anti-5hmC antibody, positive bands for specific promoter regions in the Ccny and Cdk16 genes can be obtained by PCR ( Figure 5G , Figure S2 ). However, after fisetin treatment of HuRCSCs, almost no positive bands for specific promoter regions in the Ccny and Cdk16 genes can be obtained by PCR ( Figure 5H , Figure S2 ). Therefore, the experiment results showed that fisetin can inhibit endogenous TET1 activity in HuRCSCs to reduce 5hmC modification in the specific promoter regions in the Ccny and
Cdk16 genes and decrease CCNY/CDK16 protein activity. In the present study, we investigated two questions: First, does fisetin have significant inhibitory effects on the in vivo and in vitro [25] [26] [27] Some studies pointed out that the TET1 protein contains a nuclear localisation sequence and can bind to DNA. [25] [26] [27] Therefore, TET1 mainly carries out its physiological functions in the cell nucleus. At the same time, TET1 is highly expressed mainly in foetal tissues and stem cells. [25] [26] [27] Based on the aforementioned clues, we analysed the 5hmC modification status on CpG islands in the promoter regions of CCNY and CDK16. The experiment results showed that the overall 5hmC modification levels of genomic DNA in fisetin-treated renal cancer stem cells were significantly reduced. At the same time, 5hmC modification on the CpG islands in the promoter regions of CCNY and CDK16
was significantly decreased. We suggested that this phenomenon is directly associated with down-regulation of TET1 protein expression ( Figure 6 ).
Therefore, in summary, we found that fisetin inhibits the epigenetic mechanism in renal cancer stem cells, that is, fisetin inhibits TET1 expression and reduces 5hmC modification in specific loci in the promoters of CCNY/CDK16 in renal cancer stem cells. This inhibits transcription of these genes, causing cell cycle arrest and ultimately inhibiting renal cancer stem cell division.
